Texas
LATEST FROM BIOSPACE
Do you wake up every morning dreading going to work? If this happens to you even once a week, it may be time to start looking for a new gig.
Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
Biopharma companies strengthen their leadership and boards with these appointments.
AuroLase Therapy is a focal ablation treatment utilizing gold nanoparticles. The nanoparticles heat and destroy cancer cells.
Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States.
Researchers led by Texas A&M University’s College of Veterinary Medicine & Biomedical Sciences have identified a new pathway they believe may help suppress the development of glioblastoma tumors.
Part of the new corporate park will be used to expand the company’s blood-based diagnostic tests in addition to blood-based molecular profiling and increasing research and development capacity.
Carbon nanotubes are a type of nanomaterials made up of a two-dimensional lattice of carbon atoms. Researchers at Texas Heart Institute recently used bio-compatible nanotubes invented at Rice University to restore electrical function to damaged hearts.
The deal has a flexible framework, which will allow for a variety of projects at different stages of development over several years.
The pooled data results came five months after the FDA rejected Zynquista following a split advisory committee vote.
PRESS RELEASES